These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 27882559)
1. Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. Lilienberg E; Dubbelboer IR; Sjögren E; Lennernäs H J Pharm Pharmacol; 2017 Feb; 69(2):135-142. PubMed ID: 27882559 [TBL] [Abstract][Full Text] [Related]
2. The effects of lipiodol and cyclosporin A on the hepatobiliary disposition of doxorubicin in pigs. Dubbelboer IR; Lilienberg E; Hedeland M; Bondesson U; Piquette-Miller M; Sjögren E; Lennernäs H Mol Pharm; 2014 Apr; 11(4):1301-13. PubMed ID: 24558959 [TBL] [Abstract][Full Text] [Related]
3. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms. Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458 [TBL] [Abstract][Full Text] [Related]
5. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies. Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185 [TBL] [Abstract][Full Text] [Related]
6. In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Lilienberg E; Dubbelboer IR; Karalli A; Axelsson R; Brismar TB; Ebeling Barbier C; Norén A; Duraj F; Hedeland M; Bondesson U; Sjögren E; Stål P; Nyman R; Lennernäs H Mol Pharm; 2017 Feb; 14(2):448-458. PubMed ID: 27997198 [TBL] [Abstract][Full Text] [Related]
7. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849 [TBL] [Abstract][Full Text] [Related]
8. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads. Choi JW; Cho HJ; Park JH; Baek SY; Chung JW; Kim DD; Kim HC PLoS One; 2014; 9(12):e115898. PubMed ID: 25551760 [TBL] [Abstract][Full Text] [Related]
9. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670 [TBL] [Abstract][Full Text] [Related]
10. In vivo effect of oracin on doxorubicin reduction, biodistribution and efficacy in Ehrlich tumor bearing mice. Hanušová V; Tomšík P; Kriesfalusyová L; Pakostová A; Boušová I; Skálová L Pharmacol Rep; 2013; 65(2):445-52. PubMed ID: 23744429 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats. Zeng X; Cai H; Yang J; Qiu H; Cheng Y; Liu M Biomed Pharmacother; 2019 Aug; 116():108964. PubMed ID: 31102935 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics of doxorubicin alginate microspheres and evaluation of its hepatic arterial embolization in vivo]. Liu D; Wang PC; Qi XR; Zou Q; Zou YH; Hong H Yao Xue Xue Bao; 2006 Aug; 41(8):778-83. PubMed ID: 17039787 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis. Yoshida H; Goto M; Honda A; Nabeshima T; Kumazawa T; Inagaki J; Yamanaka N; Ota K Cancer Chemother Pharmacol; 1994; 33(6):450-4. PubMed ID: 8137454 [TBL] [Abstract][Full Text] [Related]
14. [Enhanced effect of hepatic arterial infused anticancer drugs on rabbit VX-2 carcinoma by means of combination with Lipiodol. Adriamycin versus Lipiodol adriamycin sandwich method and adriamycin suspended in a Lipiodol]. Hoshino M; Koyama Y; Sugano K; Kanno M; Satou N; Abe R Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2810-3. PubMed ID: 2551224 [TBL] [Abstract][Full Text] [Related]
15. Slow infusion rate of doxorubicin induces higher pro-inflammatory cytokine production. Tien CC; Peng YC; Yang FL; Subeq YM; Lee RP Regul Toxicol Pharmacol; 2016 Nov; 81():69-76. PubMed ID: 27494949 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva. Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cusack BJ; Young SP; Driskell J; Olson RD Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124 [TBL] [Abstract][Full Text] [Related]
18. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Dubbelboer IR; Lilienberg E; Sjögren E; Lennernäs H Mol Pharm; 2017 Mar; 14(3):686-698. PubMed ID: 28182434 [TBL] [Abstract][Full Text] [Related]
19. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Mosure KW; Henderson AJ; Klunk LJ; Knipe JO Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin. Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]